PATENT CLAIM ANALYSIS

Application Number: 16160554
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "093200"]

Abstract:
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a  Salmonella  strain comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth. In some aspects, the  Salmonella  strain is an attenuated  Salmonella typhimurium  strain. In other aspects, the immunosuppressive target is STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, pGE2 or VEGF. In one embodiment, the immunosuppressive target is IDO1 or Arg1 and the shRNA molecule is any one of SEQ ID NO:5-14.

Claim (Index 2):
The composition of  claim 1 , wherein the  Salmonella  strain is an attenuated  Salmonella typhimurium  strain.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 97.0
- Lexical Diversity: 1.9322
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15276645', '14065284', '15553855', '14897210', '14119452']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7037557476334322
- 35 USC 102 Novelty (BERT): 0.754319539349874
- Combined Prediction Score: 0.7088121268050763
- Mean Citation Score: 493.9250980000001
- Max Citation Score: 848.0247
- Similarity Product: 844.3595942400814

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test